Clinical and Experimental Immunology
7th International Immunoglobulin Conference: Immunodeﬁciencies
R. E. Schmidt* and H. D. Ochs† *Hannover Medical School, Hannover, Germany, and †University of Washington and Seattle Children’s Research Institute, Seattle, WA, USA
Correspondence: R. E. Schmidt. E-mail: [email protected]
Summary Awareness of the challenges involved in diagnosing and treating a heterogeneous group of immunodeficiency disorders is growing. The improvements in neonatal screening offer new methods to ensure that primary immunodeficiencies (PIDs) are diagnosed as early as possible, enabling accurate treatment and the prevention of life-threatening infections and other complications. Additionally, the need to individualize patient therapy in order to optimize both clinical outcomes and quality-of-life is obvious and is exemplified by the ability to switch between intravenous and subcutaneous immunoglobulin administration offering flexible treatment regimens. However, further research is crucial in order to determine the optimal treatment for secondary immunodeficiencies, and to gain greater understanding of the underlying causes of PIDs, including common variable immunodeficiency. The information relating to the growth of patient registries is encouraging, with approximately 25 000 patients with PIDs included in the two registries discussed. Registries such as this are vital for future research, as well as providing an educational resource.
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 178: 21
This document is a scanned copy of a printed document. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material.